Is Paracetamol Safe During Pregnancy?

TL;DR

• Paracetamol (acetaminophen) remains the preferred analgesic and antipyretic during pregnancy according to FDA, ACOG, and NICE guidance, but it is no longer considered risk-free.
• Short-term use at the lowest effective dose appears to carry minimal fetal risk; prolonged or high-dose exposure (≥28 days cumulative) has been linked in observational studies to a modest increase in neurodevelopmental concerns in offspring [1][2][3].
• Pregnant women should use paracetamol only when clinically indicated—to treat significant pain or fever—and avoid routine or prophylactic use without medical advice.

How paracetamol works and why it matters in pregnancy

Paracetamol (known as acetaminophen in North America; marketed as Tylenol, Panadol, and many generics) is the most widely used over-the-counter analgesic–antipyretic worldwide. Its mechanism of action, though studied for decades, is not fully elucidated. The drug is a weak inhibitor of prostaglandin (PG) synthesis via cyclooxygenase (COX) enzymes, and its pharmacological profile in vivo resembles that of selective COX-2 inhibitors, although it lacks meaningful anti-inflammatory potency at therapeutic doses [7]. Paracetamol also activates descending serotonergic pain-inhibiting pathways in the central nervous system and interacts with the endocannabinoid system through its metabolite N-arachidonoyl-phenolamine (AM404), which activates transient receptor potential vanilloid 1 (TRPV1) receptors and modulates cannabinoid receptor signaling [1][7].

After oral administration, paracetamol is rapidly absorbed with a mean systemic bioavailability of roughly 75%. It is extensively metabolized in the liver, primarily via glucuronidation (~55%) and sulfation (~30%), with a plasma half-life of 1.5–2.5 hours [8]. A small fraction undergoes CYP450-mediated oxidation to the reactive metabolite N-acetyl-p-benzo-quinone-imine (NAPQI), which is normally detoxified by glutathione conjugation. This metabolic pathway becomes clinically significant only in overdose situations or when glutathione stores are depleted [8].

In pregnancy, these pharmacological properties take on special significance. Paracetamol most likely crosses the placenta through passive diffusion, reaching the fetal circulation and, critically, the developing brain [2]. Because pregnancy already involves shifts in drug metabolism—increased hepatic blood flow, altered glucuronidation capacity, and changes in plasma protein binding—fetal exposure to paracetamol and its metabolites may be more variable and less predictable than in the non-pregnant state.

More than 50% of women worldwide report using paracetamol at some point during pregnancy, with headache being the most frequent indication [2]. This prevalence, combined with growing epidemiological signals of potential harm, has prompted a re-evaluation of how clinicians counsel pregnant patients about this ubiquitous medication.

Paracetamol and fetal neurodevelopment: what the evidence shows

The question that has dominated research since approximately 2013 is whether prenatal paracetamol exposure is associated with adverse neurodevelopmental outcomes, particularly attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD).

Epidemiological evidence

A growing body of observational research—comprising large prospective cohort studies, registry-based analyses, and meta-analyses—has examined this association. Several key findings have emerged:

ADHD and behavioural outcomes. Multiple cohort studies, including data from the Norwegian Mother, Father and Child Cohort Study (MoBa) and the Danish National Birth Cohort, have reported a modest but statistically significant increase in the risk of ADHD-related behaviours and hyperkinetic disorders in children exposed to paracetamol in utero, especially with prolonged use. The aggregate relative risk increase across studies is approximately 25% [1]. A 2016 analysis noted that gestational exposure exceeding 28 days was associated with motor milestone delay, gross and fine motor impairments, communication difficulties, and internalizing and externalizing behavioural problems assessed at age 3 years [3].

Autism spectrum disorder. The link between prenatal paracetamol exposure and ASD has been explored in multiple studies. A large cohort study with 12.7 years of follow-up found that gestational paracetamol exposure was associated with an increased risk of ASD, but primarily when hyperkinetic disorder was also present [3]. A systematic review that finalized 16 high-quality papers—including 13 prospective cohort studies, two reviews, and one meta-analysis—found that all included studies showed an association between acetaminophen use and neurodevelopmental outcomes, with longer duration, higher dose, and greater frequency linked to stronger associations [4].

Dose–response relationship. Several analyses point to a dose–response pattern: the longer and more frequently paracetamol is used during pregnancy, the stronger the observed association with neurodevelopmental outcomes [1][2][4]. Importantly, short-term use (a few days for an acute illness) has consistently shown little or no measurable increase in risk [2].

Limitations and confounders

These findings must be interpreted with important caveats:

• Unmeasured confounding. Observational studies cannot fully account for confounding by indication—women who take paracetamol more frequently may have underlying conditions (chronic pain, fever, infection, stress) that themselves affect fetal neurodevelopment [1][2].
• Genetic confounders. Genetic transmission of traits associated with both pain sensitivity and neurodevelopmental disorders in offspring is difficult to rule out [1].
• Recall and measurement bias. Many studies rely on self-reported paracetamol use, which introduces recall bias.
• No randomized controlled trials. Ethical constraints preclude placebo-controlled trials of medication use in pregnancy, meaning all available data are observational.

A 2021 review in the International Journal of Molecular Sciences summarized the situation clearly: the epidemiological data point to a dose–effect relationship, but they "cannot fully account for unmeasured confounders, notably indication and genetic transmission" [1].

Experimental (preclinical) evidence

Only a limited number of animal studies have examined this question. Paracetamol given to pregnant rats by gavage produced altered behaviour in offspring [1]. In neonatal mouse models (paracetamol administered at or before postnatal day 10), exposed animals exhibited altered locomotor activity in a novel home environment in adulthood and showed a blunted analgesic response to paracetamol given later in life [1]. These findings are hypothesis-generating but cannot be directly extrapolated to humans.

At the molecular level, NAPQI—the reactive paracetamol metabolite responsible for hepatotoxicity in overdose—has been shown to exert oxidative stress and deplete glutathione in brain tissue even at sub-hepatotoxic doses [1]. Whether this mechanism contributes to neurodevelopmental effects at standard therapeutic doses in humans remains unknown.

Paracetamol dosing guidance in pregnancy: current recommendations

Key point: The fact that paracetamol remains preferred over NSAIDs and opioids during pregnancy does not mean it is harmless—it means the known risks of alternatives are greater. The current consensus is to use paracetamol at the lowest effective dose for the shortest possible duration [2][6].

What international guidelines say

Regulatory and professional bodies have adopted cautious but broadly supportive positions on paracetamol use in pregnancy:

FDA (United States). Under the legacy pregnancy category system, paracetamol was classified as Category B (animal reproduction studies have not demonstrated a fetal risk, and there are no adequate, well-controlled studies in pregnant women). The FDA has not issued a formal contraindication but has acknowledged the emerging data on neurodevelopmental risks and encouraged further research [VERIFY].

ACOG (American College of Obstetricians and Gynecologists). ACOG continues to recognize paracetamol as the first-line analgesic in pregnancy. Their guidance emphasizes that untreated significant pain and high fever also carry risks to pregnancy, and that paracetamol should be used when clinically indicated [VERIFY].

NICE (United Kingdom). The National Institute for Health and Care Excellence recommends paracetamol as the analgesic of choice during pregnancy. NICE advises using the lowest effective dose for the shortest possible time [VERIFY].

EMA (European Medicines Agency). The EMA has reviewed the evidence on prenatal paracetamol exposure and neurodevelopment. While it has not changed the product labelling to include a specific warning, it acknowledges the epidemiological signals and supports ongoing pharmacovigilance [VERIFY].

WHO. The World Health Organization includes paracetamol on its Model List of Essential Medicines and does not restrict its use in pregnancy, although it recommends judicious use of any medication during gestation [VERIFY].

A consensus statement published in 2021 and signed by 91 scientists and clinicians called for heightened caution and further research, urging regulatory bodies to review the safety signals more formally [VERIFY]. This statement was notable for its breadth of signatories but also drew criticism from some obstetric organizations for potentially causing unnecessary alarm.

Adverse effects and safety profile of paracetamol in pregnancy

Red flags — when to seek immediate medical attention

• Suspected paracetamol overdose (ingestion >4 g/day or any intentional overdose): N-acetylcysteine (NAC) is the antidote and is safe in pregnancy.
• Signs of liver injury: jaundice, dark urine, severe right upper quadrant pain, persistent nausea/vomiting.
• Severe allergic reaction: facial swelling, difficulty breathing, widespread rash.

Special populations and clinical pearls

First, second, and third trimester considerations

Unlike NSAIDs—which carry specific risks in early pregnancy (possible association with miscarriage at high doses) and late pregnancy (premature closure of the ductus arteriosus, oligohydramnios)—paracetamol does not have a trimester-specific contraindication. However, the developing fetal brain may be most vulnerable during the second and third trimesters, when key neurodevelopmental processes (neuronal migration, synaptogenesis, myelination) are at their peak [1][2].

Fever management in pregnancy

Maternal fever, particularly sustained high fever (≥39°C / 102.2°F), is itself associated with adverse pregnancy outcomes including neural tube defects (first trimester) and other congenital anomalies. In this context, treating significant fever with paracetamol is not merely acceptable but recommended—the risk of untreated fever likely outweighs the risk of short-term paracetamol use [2][6].

Pain relief during labour

Paracetamol is used as part of multimodal analgesia during labour. Parenteral (intravenous) acetaminophen is included among systemic pharmacologic agents available for labour pain management, alongside opioids and nitrous oxide [6]. While epidural analgesia remains the most effective method of labour pain relief, IV paracetamol can serve as a useful adjunct, particularly when epidural is contraindicated, unavailable, or declined by the patient [6].

Breastfeeding

Paracetamol is considered compatible with breastfeeding by the AAP (American Academy of Pediatrics) and other authorities. It is excreted in breast milk in small quantities (estimated 1–2% of the maternal dose reaches the infant), which is well below the therapeutic infant dose [VERIFY].

Women with liver disease

Pregnant women with pre-existing liver disease, including intrahepatic cholestasis of pregnancy, should use paracetamol with additional caution and under medical supervision. The maximum daily dose may need to be reduced (typically to 2 g/day) in this population [VERIFY].

Alternatives to consider

When analgesia is needed in pregnancy and paracetamol is not sufficient or not appropriate:

• Non-pharmacologic approaches: Heat or cold packs, physiotherapy, acupuncture, massage, transcutaneous electrical nerve stimulation (TENS), relaxation techniques, yoga, and cognitive behavioural therapy for chronic pain [6].
• Short-course NSAIDs (second trimester only): Ibuprofen may be used cautiously between weeks 12 and 20 of gestation when paracetamol fails, but should be avoided before 12 weeks and after 20 weeks [VERIFY].
• Opioids: Reserved for severe pain, typically under specialist supervision, and with awareness of neonatal abstinence syndrome risk with prolonged use.
• Emerging therapies: VX-548, a novel NaV1.8-specific inhibitor, has shown promise in Phase II and III trials for acute pain following surgery, but safety data in pregnancy are currently absent and the drug is not approved for use in pregnant women [5].

FAQ

Q1: Can I take paracetamol for a headache while pregnant? A1: Yes. A single dose or a few days of paracetamol at standard doses (500–1000 mg every 4–6 hours, not exceeding 3–4 g/day) for an occasional headache is considered acceptable during pregnancy. The data suggesting potential harm are associated with prolonged, frequent use—not short-term, intermittent use [2]. However, if you are experiencing frequent or severe headaches, consult your healthcare provider, as this may warrant further evaluation (e.g., to rule out pre-eclampsia).

Q2: Does paracetamol cause autism? A2: The current evidence does not prove that paracetamol causes autism. Several observational studies have found a statistical association between prolonged prenatal paracetamol use and an increased risk of ASD in offspring, but these studies cannot establish causation due to uncontrolled confounders such as the underlying condition being treated, genetic factors, and other exposures [1][3][4]. Short-term use has not been reliably associated with ASD risk [2]. Regulatory bodies including the FDA and EMA have not concluded that paracetamol causes autism.

Q3: What is the safest painkiller during pregnancy? A3: Paracetamol remains the first-line analgesic recommended by ACOG, NICE, and other guidelines for use during pregnancy. It is preferred over NSAIDs (which carry risks particularly in the first and third trimesters) and opioids (which carry risks of dependence and neonatal abstinence syndrome). Non-pharmacologic pain management strategies should be considered as first-line or adjunctive therapy whenever possible [6].

Q4: How much paracetamol is too much during pregnancy? A4: Do not exceed 4 g (4000 mg) per day, and many clinicians recommend a more conservative limit of 3 g/day during pregnancy. More importantly, avoid using paracetamol daily for extended periods (weeks to months) without medical supervision. The emerging evidence on neurodevelopmental outcomes specifically implicates cumulative exposure of 28 days or more [3]. Use the lowest effective dose for the shortest necessary duration.

Q5: Should I stop taking paracetamol now that I know about these risks? A5: Not necessarily. The risks identified in observational studies are modest in magnitude and not proven to be causal. Untreated significant pain and fever also carry risks during pregnancy, including adverse effects on fetal development. The goal is not to avoid paracetamol entirely but to use it thoughtfully—when genuinely needed, at the lowest effective dose, for the shortest reasonable duration. Discuss any concerns with your prescriber or midwife [2].

References

[1] Bührer C, Endesfelder S, Scheuer T. International Journal of Molecular Sciences 2021. PMID:34681816. pubmed.ncbi.nlm.nih.gov/34681816

[2] Nilsen K, Staff AC, Krogsrud SK. Acta Obstetricia et Gynecologica Scandinavica 2023. PMID:36941046. pubmed.ncbi.nlm.nih.gov/36941046

[3] Andrade C. The Journal of Clinical Psychiatry 2016. PMID:26930528. pubmed.ncbi.nlm.nih.gov/26930528

[4] Khan FY, Kabiraj G, Ahmed MA. Cureus 2022. PMID:35989852. pubmed.ncbi.nlm.nih.gov/35989852

[5] Hang Kong AY, Tan HS, Habib AS. Pain Management 2024. PMID:39552600. pubmed.ncbi.nlm.nih.gov/39552600

[6] Zuarez-Easton S, Erez O, Zafran N. American Journal of Obstetrics and Gynecology 2023. PMID:37005099. pubmed.ncbi.nlm.nih.gov/37005099

[7] Graham GG, Scott KF. American Journal of Therapeutics 2005. PMID:15662292. pubmed.ncbi.nlm.nih.gov/15662292

[8] Prescott LF. British Journal of Clinical Pharmacology 1980. PMID:7002186. pubmed.ncbi.nlm.nih.gov/7002186

About the author

Dr. Stanislav Ozarchuk, PharmD, has 15 years of clinical pharmacy experience. He writes for PillsCard.com, the international drug encyclopedia.

Medical disclaimer

The information provided here is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.